Previous 10 | Next 10 |
Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19 Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ ...
Phase III Stem Cell Company Expands Clinical Programs to Address $10 Billion COPD Market Therapeutic Solutions International, Inc. announced today filing of an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) seeking permis...
Therapeutic Solutions International (OTCPK:TSOI) stock has jumped 25.9% to $0.03 in Monday morning trade, after the micro-cap company launched a phase 3 trial to treat patients with COVID-19 associated lung damage using its JadiCell universal donor stem cell drug. The study will enroll 1...
Landmark Study Aimed to Support FDA Registration of First Cell Therapy with Dual Anti-inflammatory and Lung Healing Mechanism of Action Therapeutic Solutions International announced today the launching of a double-blind, randomized, placebo controlled, multi-center, multi-na...
Company Plans to Leverage Current FDA Clinical Trial Clearance to Accelerate Entry into Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis Therapeutic Solutions International announced today data demonstrating its JadiCell™ adult stem cell product...
Therapeutic Solutions International announced today the correction of a statement made in a press release dated March 25, 2022, that said, among other things, that: “As part of the trial organization, the Principal Investigator has been changed to Dr. James Veltmeyer and Therapeu...
Therapeutic Solutions International (OTCPK:TSOI) said it selected Biorasi as the contract research organization (CRO) to run a phase 3 trial evaluating JadiCell Adult Stem Cell Product in patients with advanced COVID-19. The company said the trial was cleared by the FDA as a continuation of i...
Company Aims to be “First to Market” Utilizing Stem Cells to Treat and Repair COVID-19 Injured Lungs Therapeutic Solutions International announced today its Board of Directors has selected Biorasi as the contract research organization (CRO) to run its Pivotal F...
Transfer of Trial Sponsorship Final Major Milestone before Initiation of Lung Failure Pivotal Clinical Trial Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal tri...
Therapeutic Solutions International (OTCPK:TSOI) said it was issued U.S. Patent #11,266,707 titled, Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19. The company said the patent covers composition of matter and uses of QuadraMune to preve...
News, Short Squeeze, Breakout and More Instantly...
Therapeutic Sltns Intl Company Name:
TSOI Stock Symbol:
OTCMKTS Market:
Therapeutic Sltns Intl Website:
Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Tra...
Therapeutic Solutions International Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distr...
Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the abi...